Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
21.12.2016
Björn Westberg to join BONESUPPORT™ as Chief Financial Officer

Lund, Sweden, 21 December 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that Björn Westberg is to join the Company as Chief Financial Officer and Director in early 2017.

Mr Westberg brings nearly 30 years’ finance and management experience to BONESUPPORT. He joins from Recipharm AB (publ) - one of the largest pharmaceutical contract manufacturers in the world - where he has been CFO since 2007. Prior to this he was CFO of the listed (Nasdaq Stockholm) software company Jeeves (2001-2007), and before that he held senior roles at AstraZeneca, among those Finance Director ISMO Northern Europe and Controller in Astra Japan. 

Dato
19.12.2016
BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board

BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board. Tone Kvåle, CFO of Nordic Nanovector, elected as a new Board Member. 

Lund, Sweden, 16 December 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces, that Dr. Håkan Björklund has been confirmed as Chairman and that  Ms. Tone Kvåle has been elected as a  new Board Member. The appointments were made at an EGM held on 15 December 2016.

Dr. Björklund is Partner of Tellacq AB, a private investment firm. He joined the BONESUPPORT Board in September 2016 in conjunction with the Company’s $37 million (SEK 315 million) financing, which was led by Tellacq. Dr. Björklund has a long and successful track record in the healthcare industry, including as the former CEO of Nycomed, which he grew from a small Scandinavian company into a global business before its acquisition by Takeda in 2011. He is currently chairman of the board of Swedish Orphan Biovitrum AB and an Industry Executive at Avista Capital Partners.

Tone Kvåle joins as a Board Member and Head of the Audit Committee. She is currently Chief Financial Officer of Nordic Nanovector, an Oslo-listed biopharmaceutical company, and has more than 20 years’ biotech industry experience. Prior to joining Nordic Nanovector, she was CFO of NorDiag, Kavli Holding and Dynal Biotech, and has held senior management positions at Invitrogen, Life Technologies and ThermoFisher (US). Ms. Kvåle has a diploma in Finance & Administration from Harstad University College.

Richard Davies, CEO of BONESUPPORT, said: “I am extremely happy that Håkan has been elected Chairman and that Tone will be joining the Board. This is an exciting period for BONESUPPORT following our recent $37 million (SEK 315 million) financing. We are now focused on building further additional shareholder value by growing  sales of our current CERAMENT products, generating further data highlighting the clinical and health economic benefits these products deliver and progressing our pipeline. I am confident that Håkan’s and Tone’s experience will be valuable in helping us achieve our strategic goals.”

Dr. Björklund said: “I look forward to working with the management team and the Board to deliver BONESUPPORT’s potential to become a global leader in the management and treatment of bone disease based on the unique properties of its CERAMENT platform.”


Dato
16.12.2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline


Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score
compared to placebo after eight weeks of treatment with a favorable safety profile


Eczema is a chronic, inflammatory skin condition affecting millions of children and adults worldwide1 with an unmet need for effective and safe oral treatments
Dato
14.12.2016
Bonesupport - Richard Davies Wins “Best CEO in the Biomaterials Industry” Award from European CEO Magazine

Lund, Sweden, 13 December, 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, is pleased to announce that its CEO Richard Davies has won the “Best CEO in the Biomaterials Industry” award. The award was presented by European CEO Magazine based on Mr. Davies’ track record at the forefront of major new healthcare trends and the continuing success of BONESUPPORT™ under his leadership.

Mr. Davies became CEO of BONESUPPORT in January 2016, following nearly four years spent at Hospira, where he served as Chief Commercial Officer. While at Hospira, he drove growth, globalization and modernization across the business. Hospira was acquired by Pfizer at the end of 2015. Prior to Hospira, Mr. Davies spent nine years in increasingly senior leadership positions at Amgen in Europe, Australia and the U.S. His roles included leadership of the U.S. Inflammation sales group, which commercialized Enbrel® (etanercept), the most prescribed biologic medicine in the U.S. at that time. Mr. Davies began his career at Eli Lilly, spending 13 years in increasingly senior positions. 

Dato
30.11.2016
Vtesse Receives Rare Pediatric Disease Designation by the FDA for VTS-270 for the Treatment of Niemann-Pick Type C1 Disease
GAITHERSBURG, Md., Nov. 29, 2016 /PRNewswire/ -- Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to VTS-270, the company's investigational drug for children with Niemann-Pick Type C1 disease (NPC). NPC is a progressive, irreversible, chronically debilitating – and ultimately lethal – genetic disease. 
Dato
17.11.2016
Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules

New York and Paris, November 16, 2016

Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-derived biomarkers in an effort to improve clinical outcomes for patients treated with Bristol-Myers Squibb’s Immuno-Oncology portfolio.

Dato
07.11.2016
Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
Ness Ziona, Israel – Nov 3, 2016 – Atox Bio, a clinical stage company developing novel immunemodulators for critically ill patients with severe infections, today announced the independent Data Monitoring Committee (DMC) completed its pre-planned safety review of the first 50 patients enrolled in the company’s ACCUTE trial and recommended that the study, evaluating novel candidate AB103 for the treatment of Necrotizing Soft Tissue Infections (“Flesh Eating Bacteria”), continue without modification.  
Dato
01.11.2016
scPharmaceuticals Announces Presentation on Subcutaneous Ceftriaxone at IDWeek 2016

-Complete bioavailability after subcutaneous administration of ceftriaxone

- Equivalent antimicrobial coverage (time over MIC) to standard intravenous administration

Lexington, MA., October 31, 2016 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the presentation of study results at IDWeek 2016 in New Orleans, Louisiana.

Dato
27.10.2016
BONESUPPORT™ Raises $37 million (SEK 327 million) to Drive Product Sales and Deliver Further Value from CERAMENT™ Injectable Drug Eluting Bioceramic Platform

Dr. Håkan Björklund of Tellacq AB, former CEO of Nycomed, becomes Chairman-Elect 

CERAMENT BVF, CERAMENT G AND CERAMENT V continue to increase sales rapidly driven by a growing body of compelling clinical data

Lund, Sweden, 27 October 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that it has raised $37 million (SEK 327 million) in a combination of equity and debt finance. These new funds will be used to deliver further value from its unique CERAMENT platform. The oversubscribed equity financing was led by Tellacq AB and was supported by the Company’s current major shareholders, including HealthCap, Lundbeckfond Ventures, Industrifonden, AP3 (The Third Swedish National Pension Fund)  and Carl Westin. The debt finance was provided by Kreos Capital. 

Dato
20.10.2016
SANIFIT ANNOUNCES INITIATION OF FIRST CLINICAL TRIAL OF SNF472 IN PATIENTS WITH CALCIPHYLAXIS
San Diego, USA and Palma, Spain, October 20, 2016 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced successful initiation of the first clinical trial of its lead candidate, SNF472, for the treatment of the orphan disease calciphylaxis (calcific uraemic arteriolopathy, CUA).
Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste